Kevin R Kelly

Kevin R Kelly

UNVERIFIED PROFILE

Are you Kevin R Kelly?   Register this Author

Register author
Kevin R Kelly

Kevin R Kelly

Publications by authors named "Kevin R Kelly"

Are you Kevin R Kelly?   Register this Author

38Publications

1100Reads

15Profile Views

Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activity.

Blood Adv 2019 Apr;3(8):1318-1329

Division of Translational and Regenerative Medicine, Department of Medicine, The University of Arizona Comprehensive Cancer Center, Tucson, AZ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018026484DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482361PMC
April 2019

Oncolytic Viruses for Multiple Myeloma Therapy.

Cancers (Basel) 2018 Jun 14;10(6). Epub 2018 Jun 14.

Division of Translational and Regenerative Medicine, Department of Medicine and The University of Arizona Cancer Center, Tucson, AZ 85724, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers10060198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025383PMC
June 2018

Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus.

Oncotarget 2015 Dec;6(38):41275-89

Department of Medicine and The Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center, San Antonio, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.5753DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747405PMC
December 2015

Clinical use of proteasome inhibitors in the treatment of multiple myeloma.

Pharmaceuticals (Basel) 2014 Dec 24;8(1):1-20. Epub 2014 Dec 24.

Internal Medicine, Jane Anne Nohl Division of Hematology, Keck School of Medicine of University of Southern California, Los Angeles, CA 90033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ph8010001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381198PMC
December 2014

Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer.

Clin Cancer Res 2013 Jul 30;19(13):3577-90. Epub 2013 Apr 30.

Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-3212DOI Listing
July 2013

Metabolism of patupilone in patients with advanced solid tumor malignancies.

Invest New Drugs 2013 Jun 18;31(3):605-15. Epub 2012 Jul 18.

Institute For Drug Development, Cancer Therapy and Research Center at the University of Texas Health Science Center, San Antonio, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-012-9838-2DOI Listing
June 2013

Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.

Int J Cancer 2012 Dec 28;131(11):2693-703. Epub 2012 Jun 28.

Division of Hematology and Medical Oncology, Cancer Therapy and Research Center, The University of Texas Health Science Center, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.27579DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419336PMC
December 2012

MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy.

Expert Opin Investig Drugs 2012 Oct 16;21(10):1563-73. Epub 2012 Jul 16.

The University of Texas Health Science Center at San Antonio, Cancer Therapy and Research Center, MC8232, 7979 Wurzbach Rd, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2012.707192DOI Listing
October 2012

Autophagy as a target for cancer therapy: new developments.

Cancer Manag Res 2012 11;4:357-65. Epub 2012 Oct 11.

The Department of Medicine and Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center, San Antonio, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S26133DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474143PMC
October 2012

Targeting aurora kinases in cancer treatment.

Curr Drug Targets 2011 Dec;12(14):2067-78

The Institute for Drug Development, CTRC at University of Texas Health Science Center, 14960 Omicron Drive, San Antonio, TX 78245, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138945011798829410DOI Listing
December 2011

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib.

J Cell Mol Med 2011 Oct;15(10):2057-70

Department of Medicine, Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, San Antonio, TX 78245, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1582-4934.2010.01218.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394217PMC
October 2011

A prospective randomised study of a rotary powered device (OnControl) for bone marrow aspiration and biopsy.

J Clin Pathol 2011 Sep 23;64(9):809-13. Epub 2011 May 23.

Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2011-200047DOI Listing
September 2011

Mammalian target of rapamycin as a target in hematological malignancies.

Target Oncol 2011 Mar 17;6(1):53-61. Epub 2011 Apr 17.

Institute for Drug Development, Cancer Therapy & Research Center, University of Texas Health Science Center, 7979 Wurzbach Rd, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-011-0175-8DOI Listing
March 2011

Mechanisms of mTOR inhibitor resistance in cancer therapy.

Target Oncol 2011 Mar 9;6(1):17-27. Epub 2011 Mar 9.

Department of Medicine and Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center, 14960 Omicron Drive, San Antonio, TX 78245, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-011-0167-8DOI Listing
March 2011

Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis.

J Biol Chem 2011 Feb 10;286(8):6602-13. Epub 2010 Dec 10.

Department of Medicine, Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center, San Antonio, Texas 78245, USA.

View Article

Download full-text PDF

Source
http://www.jbc.org/lookup/doi/10.1074/jbc.M110.151324
Publisher Site
http://dx.doi.org/10.1074/jbc.M110.151324DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3057822PMC
February 2011

Rotary powered device for bone marrow aspiration and biopsy yields excellent specimens quickly and efficiently.

J Clin Pathol 2010 Jun 19;63(6):562-5. Epub 2010 Apr 19.

University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jcp.2009.072843DOI Listing
June 2010

Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.

Blood 2010 May 4;115(18):3796-800. Epub 2010 Mar 4.

Institute for Drug Development, Cancer Therapy and Research Center at the University of Texas Health Science Center at San Antonio, San Antonio, TX 78245, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2009-11-25
Publisher Site
http://dx.doi.org/10.1182/blood-2009-11-254862DOI Listing
May 2010

Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.

Clin Cancer Res 2010 Jan 22;16(1):141-53. Epub 2009 Dec 22.

Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center, San Antonio, Texas 78245, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-1385DOI Listing
January 2010

Clinical activity of laromustine (Onrigin™) in hematologic malignancies.

Expert Rev Hematol 2009 Oct;2(5):481-8

Institute for Drug Development, Cancer Therapy and Research Center at the UT Health Science Center, University of Texas, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/ehm.09.38DOI Listing
October 2009

Emerging drugs in the treatment of pancreatic cancer.

Expert Opin Emerg Drugs 2009 Jun;14(2):311-28

Institute of Drug Development, Division of Cancer Research and Therapy Center, University of Texas Health Science Center, San Antonio, Texas 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728210902972502DOI Listing
June 2009